Drugs / Iomeprol
Iomeprol
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | IOMERVU | — | 2024-11-27 | fda.gov ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00280410 | Feb → Oct 2006 | liver disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06062134 | Oct → Dec 2023 | — | Philippe Gauthier | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 4 | NCT01255722 Comparator | Nov 2010 → Sep 2012 | coronary artery disorder | Guerbet | Completed | No outcome recorded |
| Phase 4 | NCT00390585 Comparator | Jul 2006 → Jan 2008 | chronic kidney disease, coronary atherosclerosis | German Heart Center Munich | Completed | Missed primary |
| — | NCT06965790 Comparator | Apr 2025 → Mar 2026 overdue | — | University Hospital Augsburg | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2008-05-22 | Eisai Inc. | Regulatory NON-IONIC CONTRAST AGENTS, IOMERON® 350 AND IOMERON® 350 SYRINGE, RECEIVE APPROVAL FOR USE IN DYNAMIC CT LIVER IMAGING eisai.com ↗
Bracco-Eisai Co., Ltd. (Headquarters: Tokyo, President: Osamu Hirano), an associate company of Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito), announced that its non-ionic contrast agents, Iomeron ® 350 and Iomeron ® 350 syringe (generic name: iomeprol), received additional approval for usage in dynamic computed tomography of the liver imaging (dynamic CT). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-05-22 | Eisai Inc. | NON-IONIC CONTRAST AGENTS, IOMERON® 350 AND IOMERON® 350 SYRINGE, RECEIVE APPROVAL FOR USE IN DYNAMIC CT LIVER IMAGING eisai.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iomeprol | “20 mL of injectate containing 18 mL ropivacaine 0.5% with 2 mL of radiopaque contrast (Iomeron 300: 61.24% w/v of Iomeprol equivalent to 30% iodine or 300 mg iodine/mL (Bracco...” NCT06062134 ↗ |
| Known as | E7337 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00280410 ↗ |
| Known as | Imeron 350 | “standardized contrast agent (Imeron 350, active ingredient Iomeprol) quantity (0.35 g iodine/kg)” NCT06965790 ↗ |
| Known as | Iomeron 300 | “20 mL of injectate containing 18 mL ropivacaine 0.5% with 2 mL of radiopaque contrast (Iomeron 300: 61.24% w/v of Iomeprol equivalent to 30% iodine or 300 mg iodine/mL (Bracco...” NCT06062134 ↗ |
| Known as | Iomervu | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107214 ↗ |
| Modality | Diagnostic / imaging agent | “Iomeprol 350 is used as contrast media while coronary intervention.” NCT00390585 ↗ |
| Route | Intravenous | “Patients were IV injected with a single dose of iomeprol before a coronary CT angiography” NCT01255722 ↗ |